Alpha Tau Medical Ltd is a clinical-stage medical technology company specializing in targeted alpha radiation therapy for the treatment of solid tumors. The company’s proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) platform uses implantable sources of radium-224 to deliver high-energy, short-range alpha particles directly to cancerous tissue, aiming to maximize tumor control while sparing surrounding healthy cells.
The Alpha DaRT platform comprises biodegradable seeds that are positioned in or around the tumor using standard image-guided procedures. Once in place, the seeds emit alpha radiation, which penetrates only a few cell diameters, allowing for potent localized therapy. Alpha Tau Medical is conducting clinical studies in multiple indications, including head and neck cancers and skin malignancies, in collaboration with leading oncology centers across Europe and North America.
Founded in 2010 and headquartered in Ness Ziona, Israel, Alpha Tau Medical operates additional research and manufacturing facilities in the United States. The company completed a U.S. listing in 2021 through a special purpose acquisition company (SPAC) transaction and is traded on the NASDAQ under the symbol DRTSW. Through its global network of academic and clinical partners, Alpha Tau Medical continues to advance its clinical development programs and prepare for potential regulatory filings.
Alpha Tau Medical is led by Chief Executive Officer Danny Milstein, supported by a management team with extensive experience in radiopharmaceutical development and oncology. The company remains focused on expanding its international footprint, forging strategic partnerships and ultimately bringing targeted alpha therapies into routine cancer care.
AI Generated. May Contain Errors.
